Key result
Tedisamil appears to be effective for rhythm restoration in acute-onset atrial fibrillation patients, with potential added benefits from its anti-ischemic effects.
Why the study?
Does tedisamil improve rhythm restoration in patients with acute-onset atrial fibrillation?
Does tedisamil improve rhythm restoration in patients with acute-onset atrial fibrillation?
Tedisamil is a novel multichannel potassium channel blocker that shows promise for rhythm restoration in acute-onset atrial fibrillation.
May support randomized evaluation of tedisamil for acute AF; leaves open clinical adoption pending confirmatory trials.
BACKGROUND: Even established and effective antiarrhythmic drugs (AADs) in atrial fibrillation (AF) are limited by their pro-arrhythmic and non-target organ side effects. Therefore the search continues for safer and effective new AADs. OBJECTIVE: This review will examine a novel AAD, tedisamil--a multichannel potassium channel blocker--and its antiarrhythmic properties, focusing on AF. METHODS: Review of the literature and studies assessing the effect of tedisamil in humans and animal models with atrial arrhythmia(s). CONCLUSION: Tedisamil appears to be effective for rhythm restoration in acute-onset AF patients. The proven anti-ischemic effect with tedisamil may be an added benefit. Further studies with tedisamil are needed to confirm its safety and long-term efficacy.
No takes yet. Share an insight, caveat, or question.
Krishnamoorthy et al. (2009) conducted a review in Atrial fibrillation. Tedisamil was evaluated. Tedisamil appears to be effective for rhythm restoration in acute-onset atrial fibrillation patients, with potential added benefits from its anti-ischemic effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: